These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23356728)

  • 41. Generalized anxiety disorder: What are we missing?
    Allgulander C
    Eur Neuropsychopharmacol; 2006 Jul; 16 Suppl 2():S101-8. PubMed ID: 16730165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Etiological factors of generalized anxiety disorder].
    Gosselin P; Laberge B
    Encephale; 2003; 29(4 Pt 1):351-61. PubMed ID: 14615705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The long-term clinical course of generalized anxiety disorder.
    Keller MB
    J Clin Psychiatry; 2002; 63 Suppl 8():11-6. PubMed ID: 12044103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and clinical features of newly diagnosed generalized anxiety disorder patients in Spanish primary care settings: the GADAP study.
    García-Campayo J; Caballero F; Perez M; López V
    Actas Esp Psiquiatr; 2012; 40(3):105-13. PubMed ID: 22723129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of first depression or generalized anxiety disorder episode in adults in primary care: A systematic metareview.
    Driot D; Bismuth M; Maurel A; Soulie-Albouy J; Birebent J; Oustric S; Dupouy J
    Presse Med; 2017 Dec; 46(12 Pt 1):1124-1138. PubMed ID: 29150233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New approaches to the pharmacological management of generalized anxiety disorder.
    Buoli M; Caldiroli A; Caletti E; Paoli RA; Altamura AC
    Expert Opin Pharmacother; 2013 Feb; 14(2):175-84. PubMed ID: 23282069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Generalized anxiety disorders (GAD)--a neglected illness? Background und aims of the GAD-P study].
    Wittchen HU; Linden M; Schwarzer W; Riemann D; Boerner RJ; Bandelow B
    Fortschr Med Orig; 2001; 119 Suppl 1():1-4. PubMed ID: 11935662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment.
    Belzer K; Schneier FR
    J Psychiatr Pract; 2004 Sep; 10(5):296-306. PubMed ID: 15361744
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.
    Rovira J; Albarracin G; Salvador L; Rejas J; Sánchez-Iriso E; Cabasés JM
    Community Ment Health J; 2012 Jun; 48(3):372-83. PubMed ID: 22484993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Generalized anxiety disorder in primary care. Patterns of healthcare utilization in Germany].
    Wittchen HU; Härtling S; Dukes E; Morlock R; Edelsberg J; Oster G; Berger A
    MMW Fortschr Med; 2012 Oct; 154 Suppl 3():77-84. PubMed ID: 23133883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study.
    Ansseau M; Fischler B; Dierick M; Mignon A; Leyman S
    Eur Psychiatry; 2005 May; 20(3):229-35. PubMed ID: 15935421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An overview of generalized anxiety disorder: disease state--appropriate therapy.
    Lydiard RB
    Clin Ther; 2000; 22 Suppl A():A3-19; discussion A20-4. PubMed ID: 10815647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity?
    Maier W; Gänsicke M; Freyberger HJ; Linz M; Heun R; Lecrubier Y
    Acta Psychiatr Scand; 2000 Jan; 101(1):29-36. PubMed ID: 10674948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Framing the process in the implementation of care for people with generalized anxiety disorder in primary care: a qualitative evidence synthesis.
    Toledo-Chávarri A; Ramos-García V; Torres-Castaño A; Trujillo-Martín MM; Peñate Castro W; Del Cura-Castro I; Serrano-Aguilar P; Perestelo-Pérez L
    BMC Fam Pract; 2020 Nov; 21(1):237. PubMed ID: 33218311
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generalized anxiety disorder in urban China: Prevalence, awareness, and disease burden.
    Yu W; Singh SS; Calhoun S; Zhang H; Zhao X; Yang F
    J Affect Disord; 2018 Jul; 234():89-96. PubMed ID: 29524751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder.
    Buoli M; Caldiroli A; Serati M
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):351-359. PubMed ID: 28075650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anxiety disorders: does one treatment fit all?
    Baldwin D
    Int J Psychiatry Clin Pract; 2004; 8 Suppl 1():31-5. PubMed ID: 24930687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Developing a European research network to address unmet needs in anxiety disorders.
    Baldwin DS; Pallanti S; Zwanzger P
    Neurosci Biobehav Rev; 2013 Dec; 37(10 Pt 1):2312-7. PubMed ID: 23313646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review.
    Haller H; Cramer H; Lauche R; Gass F; Dobos GJ
    BMC Psychiatry; 2014 May; 14():128. PubMed ID: 24886240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives.
    Connor KM; Davidson JR
    Biol Psychiatry; 1998 Dec; 44(12):1286-94. PubMed ID: 9861471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.